Piedmont Oncology Clinical Research Studies Table

Contacts: Marcus Bryan: 404.823.2036, Marcus.Bryan@piedmont.org

Tumor Site Study Name Participating Principal Lead CRC Indication Intervention
Locations Investigator
Solid Tumor Atreca SHAIR PAH, PHH, PFH, Trevor Valarie Latham Solid Tumor, Observational, blood samples for anti-tumor
PNH Feinstein, MD Advanced response
Solid Tumor BioAtla PAH Eyal Meiri, Sharon Joseph Solid Tumor, BA3071 in Combination with Nivolumab
MD Advanced
Breast Wellness PAH, PHH, PFH, Trevor Valarie Latham Class 2 Obesity Dietary and exercise coaching x 6 months.
Weight PNH Feinstein, MD Breast
Breast NRG-BR007 PAH, PHH, PFH, Adam Valarie Latham Stage I, BRT + endocrine therapy or No BRT +
PNH Nowlan, MD Oncotype<=18 endocrine
GI NRG-GI008 PAH, PHH, PFH, Eyal Meiri, Sharon Joseph Stage III/Stage II Colon Adjuvant Chemotherapy Based on
PNH MD ctDNA +ve Evaluation of Residual Disease
Resected Colon
GI NRG-CC005 PAH Adam Sharon Joseph Non-Advance Five or Ten Year Colonoscopy for 1-2 Non
Nowlan, MD Adenomatous Advanced Adenomatous Polyps.
Polyps
All Cancer, A222004 PAH, PHH, PFH, Adam Tia Dixon Cancer/anorexia, Olanzapine Versus Megestrol Acetate for
non- PNH Nowlan, MD non-hormone Cancer-Associated Anorexia.
hormone sensitive
sensitive
All Cancer Financial PAH, PHH, PFH, Dionne Jean Dionne Jean New cancer Survey- Observational Study of Financial Strain
Strain PNH, PMM diagnosis Among Cancer Patients.
Lung Optune Lua PAH Adam Sharon Joseph Malignant Pleural Optune Lua System Humanitarian Device
Nowlan, MD Mesothelioma Exemption Study
CNS ONO-4509 PAH Erin Dunbar, Dionne Jean Primary CNS Tirabrutinib in patients with Primary Central
MD Lymphoma Nervous System Lymphoma (PCNSL).
Brain NRG-BN003 PAH, PHH, PFH, Adam Sharon Joseph Meningioma, Observation Versus Irradiation
PNH Nowlan, MD Grade II, post
resection
Prostate NRG-GU010 PAH, PFH Adam Sharon Joseph Prostate Cancer, Randomized Trials of Unfavorable
Nowlan, MD Intermediate risk Intermediate Risk Prostate Cancer: De-
Intensification and Intensification
Prostate NRG-GU011 PAH, PFH Adam Tia Dixon Oligometastatic Radiotherapy with or without Androgen
Nowlan, MD Prostate Cancer Deprivation- Placebo controlled
randomization
Brain A071401 PAH Erin Dunbar, Tia Dixon Progressive SMO/AKT/NF2/CDK Inhibitors
MD Meningiomas with
SMO/AKT/NF2/CDK
Pathway Mutations
Brain CCTG CE.7 PAH Adam Sharon Joseph 5 or more brain Stereotactic Radiosurgery or Hippocampal-
Nowlan, MD metastases Avoidant Whole Brain Radiotherapy plus
Memantine
Brain CNS-201 PAH Erin Dunbar, Dionne Jean Recurrent Randomized control arm of intravenously
MD Glioblastoma infused Berubicin
Multiforme after
failure of standard
first line therapy
Brain GTM-101 PAH Adam Sharon Joseph Intracranial brain Multicenter observational, GammaTile
Nowlan, MD neoplasms Surgically Targeted Radiation Therapy (STaRT)
Brain GTM-103 PAH Adam Sharon Joseph Newly diagnosed Resection and GammaTile followed by
Nowlan, MD Glioblastoma Concomitant External Beam Radiation
Therapy (EBRT) and Temozolomide (TMZ) and
Adjuvant TMZ
Brain Imvax PAH Erin Dunbar, Sharon Joseph Newly diagnosed Randomized, Multicenter, Double-Blind,
ImmuneSense MD Glioblastoma Placebo-Controlled, Phase 2b Study to Assess
the Safety and Efficacy of IGV-001, an
Autologous Cell Immunotherapy with
Antisense Oligonucleotide (IMV-001)
Targeting IGF-1R
Brain NIP-GBMFTP- PAH Erin Dunbar, Dionne Jean Newly diagnosed Analysis of cell count, variability, and other
01 (Imvax MD Glioblastoma variables in developing IGV-001
Tissue
Collection)
Prostate MGC018-03 PNH, PAH, PHH, Windy Dean- Valarie Latham Metastatic MGC018 versus Androgen Receptor Axis-
PFH, PW Colomb, MD Castration- Targeted Therapy (Abiraterone or
Resistant Prostate Enzalutamide)
Cancer
Breast ML43171 PNH Windy Dean- Valarie Latham ER-Positive, HER2- Giredestrant plus Everolimus compared with
Colomb, MD Negative, Locally Exemestane plus Everolimus
Advanced or
Metastatic Breast
Cancer
Brain NRG-BN009 PAH Adam Sharon Joseph First or Second Salvage Stereotactic Radiosurgery (SRS) or SRS
Nowlan, MD Distant Brain + Hippocampal-Avoidant Whole Brain
Relapse after Radiotherapy
Upfront SRS within
Brain Metastasis
Velocity ≥ 4 Brain
Metastases/Year
Brain NRG-BN012 PAH Adam Sharon Joseph Resectable brain Pre-Operative compared to Post-Operative
Nowlan, MD metastases Stereotactic Radiosurgery
Endometrial NRG-GY026 PAH Leda Gattoc, Sharon Joseph HER2-Positive, Paclitaxel/Carboplatin alone or combined with
MD Stage I-IV either Trastazumab and Hyaluronidase-OYSK
Endometrial Serous (Herceptin Hylecta) or Pertuzumab,
Carcinoma or Trastuzumab, and Hyaluronidase-ZZXF
Carcinosarcoma (Phesgo)

Brain NU 16C02 PAH Erin Dunbar, Dionne Jean Recurrent or Combining Optune with concurrent
MD Progressive Bevacizumab
Meningioma
Breast Triple PAH Bradley Sharon Joseph Triple Negative Role of androgen receptor
Negative Butler, MD Breast Cancer
Breast
Cancers
Brain GBM Agile PAH Erin Dunbar, Dionne Jean Newly diagnosed Randomization to treatment arm or control
MD (ND) and recurrent arm based on ND or recurrent diagnosis
Glioblastoma
(GBM)